☆ 4.2 Meeting Abstract

CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design

NEUROMUSCULAR DISORDERS (2015)

Journal

NEUROMUSCULAR DISORDERS

Volume 25, Issue -, Pages S262-S262

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.nmd.2015.06.278

Keywords

-

Categories

Clinical Neurology Neurosciences

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.